Title |
Muscle relaxants for pain management in rheumatoid arthritis
|
---|---|
Published in |
Cochrane database of systematic reviews, January 2012
|
DOI | 10.1002/14651858.cd008922.pub2 |
Pubmed ID | |
Authors |
Bethan L Richards, Samuel L Whittle, Rachelle Buchbinder |
Abstract |
Pain management is a high priority for patients with rheumatoid arthritis (RA). Muscle relaxants include drugs that reduce muscle spasm (for example benzodiazepines such as diazepam (Valium), alprazolam (Xanax), lorazepam (Ativan) and non-benzodiazepines such as metaxalone (Skelaxin) or a combination of paracetamol and orphenadrine (Muscol)) and drugs that prevent increased muscle tone (baclofen and dantrolene). Despite a paucity of evidence supporting their use, antispasmodic and antispasticity muscle relaxants have gained widespread clinical acceptance as adjuvants in the management of patients with chronic musculoskeletal pain. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 8 | 24% |
United Kingdom | 4 | 12% |
Spain | 2 | 6% |
Australia | 2 | 6% |
Colombia | 2 | 6% |
France | 2 | 6% |
India | 1 | 3% |
Ireland | 1 | 3% |
Italy | 1 | 3% |
Other | 1 | 3% |
Unknown | 9 | 27% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 30 | 91% |
Science communicators (journalists, bloggers, editors) | 1 | 3% |
Scientists | 1 | 3% |
Practitioners (doctors, other healthcare professionals) | 1 | 3% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Colombia | 1 | <1% |
United Kingdom | 1 | <1% |
Peru | 1 | <1% |
Sri Lanka | 1 | <1% |
Spain | 1 | <1% |
United States | 1 | <1% |
Unknown | 311 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 43 | 14% |
Student > Ph. D. Student | 34 | 11% |
Student > Bachelor | 34 | 11% |
Researcher | 29 | 9% |
Student > Doctoral Student | 24 | 8% |
Other | 65 | 21% |
Unknown | 88 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 97 | 31% |
Nursing and Health Professions | 28 | 9% |
Psychology | 22 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 17 | 5% |
Neuroscience | 7 | 2% |
Other | 41 | 13% |
Unknown | 105 | 33% |